Sr; at. wt 87.62; at. no. 38; valence 2. Group IIA (2). Alkaline earth metal. Naturally occurring, stable isotopes: 88 (82.58%); 86 (9.86%); 87 (7.00%); 84 (0.56%). Known radioactive isotopes: 76-83, 85, 89, 90 (longest lived isotope, T 28.78 yr, β decay), 91-102. Occurs in the minerals, celestine (SrSO4) and strontianite (SrCO3); found in small quantities associated with calcium or barium minerals. Abundance in earth's crust 384 ppm. First prepared in 1807 by Davy. Commercial production by thermal reduction of strontium oxide with aluminum. Prepn: Glascock, J. Am. Chem. Soc. 32, 1222 (1910); Matignon, Compt. Rend. 177, 1116 (1923); J. Chem. Soc. 126[ii], 44 (1924); Guntz et al., cited in Gmelins, Strontium (8th ed.) 29, 35 (1931). Reviews: Goodenough, Stenger, “Magnesium, Calcium, Strontium, Barium and Radium” in Comprehensive Inorganic Chemistry vol. 1, J. C. Bailar, Jr. et al., Eds. (Pergamon Press, Oxford, 1973) pp 591-774; Chemistry of the Elements N. N. Greenwood, A. Earnshaw, Eds. (Pergamon Press, New York, 1984) pp 117-154; S. G. Hibbins in Kirk-Othmer Encyclopedia of Chemical Technology vol. 22 (Wiley-Interscience, New York, 4th ed., 1997) pp 947-955. Review of clinical use of 89Sr in pain palliation for metastatic bone cancer: G. B. Altman, C. A. Lee, Oncol. Nurs. Forum 32, 523-527 (1996). Review of toxicology and human exposure: Toxicological Profile for Strontium (PB2004-104400, 2004) 445 pp.
89Sr as antineoplastic (radiation source).
Strontium 89Sr: Antineoplastic (Radiation Source)